DoH Policies screened during the period: 1st April 2019 - 30th June 2019
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
- NICE Technology Appraisal TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
- NICE Technology Appraisal TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
- NICE Technology Appraisal TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
- NICE Technology Appraisal TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
- NICE Technology Appraisal TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
- Eligibility for HSC-funded IVF and related treatments
- High Level Equality Screening Budget
- The Firefighters’ Pension Scheme (Amendment and Transitional Provisions) Order (Northern Ireland) 2019 – Contribution Holidays